X Square Capital LLC Lowers Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

X Square Capital LLC cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 72.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,182 shares of the company’s stock after selling 158,981 shares during the quarter. X Square Capital LLC’s holdings in Teva Pharmaceutical Industries were worth $1,348,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $38,550,000. Blair William & Co. IL increased its position in Teva Pharmaceutical Industries by 9.4% in the fourth quarter. Blair William & Co. IL now owns 11,232 shares of the company’s stock worth $248,000 after buying an additional 963 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Teva Pharmaceutical Industries by 9.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 807,886 shares of the company’s stock worth $17,159,000 after acquiring an additional 70,978 shares during the period. Korea Investment CORP raised its position in shares of Teva Pharmaceutical Industries by 72.0% during the 4th quarter. Korea Investment CORP now owns 381,955 shares of the company’s stock valued at $8,418,000 after purchasing an additional 159,899 shares during the period. Finally, Financial Counselors Inc. lifted its position in shares of Teva Pharmaceutical Industries by 24.2% in the fourth quarter. Financial Counselors Inc. now owns 70,147 shares of the company’s stock valued at $1,546,000 after acquiring an additional 13,675 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 1.1 %

TEVA stock opened at $15.52 on Friday. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a market capitalization of $17.60 billion, a P/E ratio of -10.71, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The firm’s fifty day simple moving average is $17.35 and its 200-day simple moving average is $18.14.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TEVA shares. UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Bank of America lowered their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. StockNews.com cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.